Corporate Overview

Elixir Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity.The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and we are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Elixir's product pipeline includes a number of programs which we believe will have significant advantages over existing products and will address unmet medical needs of the large metabolic disease markets.These include our phase III products, Glinsuna (also known by its chemical name, mitiglinide) and Metgluna (Metformin, an approved product plus mitiglinide) for the treatment of type 2 diabetes, and our ghrelin antagonist, a compound which blocks the receptor for the hormone ghrelin, which represents a potential next-generation treatment for a number of metabolic diseases.

In addition, Elixir has built upon our knowledge of ghrelin, to advance a ghrelin agonist, a compound which stimulates the receptor for ghrelin.The Company's sirtuin program is an example of how we continue to use our understanding of the pathways which slow the aging process to identify interesting targets for the development of drugs to treat metabolic disease.

[ back to top ]